Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
new option listings on July 28th » 08:30
07/28/21
07/28
08:30
07/28/21
08:30
ACHV

Achieve Life Sciences

$7.29 /

-0.35 (-4.58%)

, ADES

Advanced Emissions

$7.42 /

+0.27 (+3.78%)

, ALGS

Aligos Therapeutics

$15.07 /

-0.43 (-2.77%)

, ATCX

Atlas Technical Consultants

$8.98 /

-0.45 (-4.77%)

, BBCP

Concrete Pumping

$8.61 /

+0.13 (+1.53%)

, BTTR

Better Choice Company

$3.47 /

-0.45 (-11.48%)

, CDAK

Codiak

$16.35 /

-0.11 (-0.67%)

, CGA

China Green

$9.65 /

-0.51 (-5.02%)

, CHMI

Cherry Hill Mortgage

$9.42 /

+0.04 (+0.43%)

, CRCT

Cricut

$34.01 /

-3.02 (-8.16%)

, CRTD

Creatd

$3.17 /

-0.01 (-0.31%)

, DRTT

Dirtt Environmental

$4.18 /

+0.03 (+0.72%)

, EARN

Ellington Residential

$11.12 /

-0.06 (-0.54%)

, EPS

WisdomTree Earnings 500

$47.00 /

-0.3 (-0.63%)

, ESXB

Community Bankers Trust

$10.65 /

-0.06 (-0.56%)

, EZM

E-Z-EM

$51.80 /

-0.15 (-0.29%)

, HMLP

Hoegh LNG Partners

$17.76 /

-0.11 (-0.62%)

, ICL

ICL

$7.06 /

-0.07 (-0.98%)

, IMXI

International Money Express

$15.76 /

-0.09 (-0.57%)

, INTT

inTEST

$13.53 /

-0.65 (-4.58%)

, LIQT

LiqTech

$6.40 /

+0.19 (+3.06%)

, MDWD

MediWound

$4.08 /

+0.26 (+6.81%)

, PSJ

PwerShares Dynamic Software

$157.72 /

-2.98 (-1.85%)

, RTPY

Reinvent Technology Partners Y

$9.91 /

-0.02 (-0.20%)

, SGTX

Sigilon Therapeutics

$5.31 /

+0.32 (+6.41%)

, SIC

Select Interior Concepts

$10.47 /

+0.18 (+1.75%)

, USDP

USD Partners

$6.66 /

-0.16 (-2.35%)

, VIRI

Virios Therapeutics

$5.64 /

-0.06 (-1.05%)

, VYGG

Vy Global Growth

$9.79 /

-0.04 (-0.41%)

New option listings for…

New option listings for July 28th include Achieve Life Sciences Inc (ACHV), Advanced Emissions (ADES), Market Vectors Africa (AFK), Aligos Therapeutics Inc (ALGS), Atlas Technical Consultants Inc (Class A Stock) (ATCX), Concrete Pumping Holdings Inc (BBCP), Better Choice Company Inc (BTTR), CBX (CBX), Codiak BioSciences Inc (CDAK), China Green (CGA), Cherry Hill Mortgage (CHMI), Cricut Inc (CRCT), Creatd Inc (CRTD), WisdomTree High Dividend Fund (DHS), Dirtt Environmental Solutions Ltd (DRTT), Ellington Residential (EARN), WisdomTree SmallCap Earnings Fund (EES), WisdomTree Earnings 500 Fund (EPS), Community Bankers Trust (ESXB), WisdomTree MidCap Earnings Fund (EZM), Hoegh LNG (HMLP), IBO (IBO), Israel Chemicals (ICL), iShares Evolved US Technology ETF (IETC), iShares Edge MSCI Intl Momentum Factor ETF (IMTM), International Money Express Inc (IMXI), inTest (INTT), WisdomTree International Quality Dividend Growth Fund (IQDG), iShares Russell Top 200 (IWL), iShares Russell Top 200 Value (IWX), iShares Dow Jones US (IYY), SPDR Russell 1000 Low Volatility ETF (LGLV), LiqTech (LIQT), MediWound (MDWD), Power Shares Food And Beverage (PBJ), PowerShares S&P 500 Buy Write Portfolio (PBP), PowerShares Dynamic Media Portfolio (PBS), PowerShares FTSE RAFI Developed Markets Ex US Sm Mid Portfolio (PDN), PowerShares Dynamic Building and Construction Portfolio (PKB), PowerShares S&P SmallCap Consumer Discretionary Portfolio (PSCD), Power Shares Dynamic Software Portfolio (PSJ), Powershares Dynamic Large Cap Growth Portfolio (PWB), Powershares Dynamic Large Cap Value Portfolio (PWV), PowerShares FTSE RAFI Developed Markets ex US Portfolio (PXF), PowerShares DWA Basic Materials Momentum Portfolio (PYZ), Reinvent Technology Partners Y (Class A Stock) (RTPY), Sigilon Therapeutics Inc (SGTX), Select Interior Concepts Inc (Class A Stock) (SIC), Presidio Property Trust Inc (Class A Stock) (SQFT), USD Partners (USDP), Virios Therapeutics Inc (VIRI), Vy Global Growth (Class A Stock) (VYGG), WisdomTree Cybersecurity Fund (WCBR), Innovative Technology ETF (XITK), and SPDR NYSE Technology (XNTK).

ShowHide Related Items >><<
VIRI Virios Therapeutics
$5.64 /

-0.06 (-1.05%)

USDP USD Partners
$6.66 /

-0.16 (-2.35%)

SIC Select Interior Concepts
$10.47 /

+0.18 (+1.75%)

SGTX Sigilon Therapeutics
$5.31 /

+0.32 (+6.41%)

RTPY Reinvent Technology Partners Y
$9.91 /

-0.02 (-0.20%)

MDWD MediWound
$4.08 /

+0.26 (+6.81%)

INTT inTEST
$13.53 /

-0.65 (-4.58%)

IMXI International Money Express
$15.76 /

-0.09 (-0.57%)

ICL ICL
$7.06 /

-0.07 (-0.98%)

HMLP Hoegh LNG Partners
$17.76 /

-0.11 (-0.62%)

ESXB Community Bankers Trust
$10.65 /

-0.06 (-0.56%)

EARN Ellington Residential
$11.12 /

-0.06 (-0.54%)

DRTT Dirtt Environmental
$4.18 /

+0.03 (+0.72%)

CRTD Creatd
$3.17 /

-0.01 (-0.31%)

CRCT Cricut
$34.01 /

-3.02 (-8.16%)

CGA China Green
$9.65 /

-0.51 (-5.02%)

CDAK Codiak
$16.35 /

-0.11 (-0.67%)

BTTR Better Choice Company
$3.47 /

-0.45 (-11.48%)

BBCP Concrete Pumping
$8.61 /

+0.13 (+1.53%)

ATCX Atlas Technical Consultants
$8.98 /

-0.45 (-4.77%)

ALGS Aligos Therapeutics
$15.07 /

-0.43 (-2.77%)

ADES Advanced Emissions
$7.42 /

+0.27 (+3.78%)

ACHV Achieve Life Sciences
$7.29 /

-0.35 (-4.58%)

ACHV Achieve Life Sciences
$7.29 /

-0.35 (-4.58%)

07/22/21 Lake Street
NIH grant opens new opportunity for Achieve's cytisinicline, says Lake Street
07/20/21 Lake Street
Achieve Life weakness on Chantix news would be opportunity, says Lake Street
07/06/21 Lake Street
Achieve Life Sciences weakness a buying opportunity, says Lake Street
06/25/21 Lake Street
Achieve Life Sciences not hurt by Chantix recall, says Lake Street
ADES Advanced Emissions
$7.42 /

+0.27 (+3.78%)

ALGS Aligos Therapeutics
$15.07 /

-0.43 (-2.77%)

07/08/21 Piper Sandler
Aligos should be bought into 'catalyst rich' second half, says Piper Sandler
06/21/21 Piper Sandler
Aligos reported 'robust data' in hepatitis B virus, says Piper Sandler
06/10/21 Piper Sandler
Aligos Therapeutics has data-rich month with robust lineup, says Piper Sandler
05/17/21 Piper Sandler
Aligos Therapeutics assumed with an Overweight at Piper Sandler
ATCX Atlas Technical Consultants
$8.98 /

-0.45 (-4.77%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Stifel
Atlas Technical Consultants initiated with a Buy at Stifel
08/11/20 DA Davidson
Atlas Technical Consultants upgraded to Buy from Neutral at DA Davidson
08/11/20 DA Davidson
Atlas Technical Consultants upgraded to Buy from Neutral at DA Davidson
BBCP Concrete Pumping
$8.61 /

+0.13 (+1.53%)

06/25/21 UBS
Concrete Pumping upgraded to Buy from Neutral at UBS
06/16/21 DA Davidson
Concrete Pumping price target raised to $11 from $9 at DA Davidson
06/15/21 Baird
Concrete Pumping price target raised to $11 from $10 at Baird
04/22/21 Baird
Concrete Pumping price target raised to $9 from $8 at Baird
BTTR Better Choice Company
$3.47 /

-0.45 (-11.48%)

07/26/21 Roth Capital
Better Choice Company initiated with a Buy at Roth Capital
07/15/21 DA Davidson
Better Choice Company initiated with a Buy at DA Davidson
07/15/21 DA Davidson
Better Choice Company initiated with a Buy at DA Davidson
CDAK Codiak
$16.35 /

-0.11 (-0.67%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CGA China Green
$9.65 /

-0.51 (-5.02%)

CHMI Cherry Hill Mortgage
$9.42 /

+0.04 (+0.43%)

04/20/21 B. Riley
Cherry Hill Mortgage transferred with Buy, $11.50 target at B. Riley
11/10/20 Piper Sandler
Cherry Hill Mortgage downgraded to Neutral from Overweight at Piper Sandler
CRCT Cricut
$34.01 /

-3.02 (-8.16%)

06/10/21 Morgan Stanley
Cricut downgraded to Equal Weight from Overweight at Morgan Stanley
05/14/21 Barclays
Cricut price target raised to $28 from $26 at Barclays
04/19/21
Fly Intel: Top five analyst initiations
04/19/21 Citi
Cricut initiated with a Buy at Citi
CRTD Creatd
$3.17 /

-0.01 (-0.31%)

DRTT Dirtt Environmental
$4.18 /

+0.03 (+0.72%)

05/06/21 National Bank
Dirtt Environmental downgraded to Sector Perform from Outperform at National Bank
05/06/21 National Bank
Dirtt downgraded to Sector Perform from Outperform at National Bank
12/31/20
Fly Intel: Top five analyst calls
12/31/20 Industrial Alliance
DIRTT Environmental downgraded to Sell from Hold at Industrial Alliance
EARN Ellington Residential
$11.12 /

-0.06 (-0.54%)

11/23/20 BTIG
Ellington Residential initiated with a Buy at BTIG
EPS WisdomTree Earnings 500
$47.00 /

-0.3 (-0.63%)

ESXB Community Bankers Trust
$10.65 /

-0.06 (-0.56%)

02/03/21 Stephens
Stephens cuts Community Bankers Trust to Equal Weight as stock nears $8 target
02/03/21 Stephens
Community Bankers Trust downgraded to Equal Weight from Overweight at Stephens
EZM E-Z-EM
$51.80 /

-0.15 (-0.29%)

HMLP Hoegh LNG Partners
$17.76 /

-0.11 (-0.62%)

07/28/21 B. Riley
Hoegh LNG Partners downgraded to Neutral from Buy at B. Riley
07/28/21 B. Riley
Hoegh LNG Partners downgraded to Neutral from Buy at B. Riley
07/28/21 Barclays
Hoegh LNG Partners downgraded to Underweight from Overweight at Barclays
03/10/21 Danske Bank
Hoegh LNG Partners upgraded to Hold from Sell at Danske Bank
ICL ICL
$7.06 /

-0.07 (-0.98%)

11/23/20 Stephens
ICL downgraded to Equal Weight with $5.50 price target at Stephens
11/23/20 Stephens
ICL downgraded to Equal Weight from Overweight at Stephens
IMXI International Money Express
$15.76 /

-0.09 (-0.57%)

05/05/21 BTIG
International Money earnings selloff a buying opportunity, says BTIG
08/17/20 BTIG
International Money Express price target raised to $22 from $17 at BTIG
08/05/20 Cantor Fitzgerald
International Money price target raised to $21 from $11 at Cantor Fitzgerald
08/05/20 JMP Securities
International Money Express upgraded to Outperform at JMP Securities
INTT inTEST
$13.53 /

-0.65 (-4.58%)

05/10/21 Lake Street
inTEST price target raised to $16 from $11 at Lake Street
03/08/21 Lake Street
inTEST price target raised to $11 from $6 at Lake Street
LIQT LiqTech
$6.40 /

+0.19 (+3.06%)

10/15/20 Stephens
LiqTech resumed with an Equal Weight at Stephens
10/02/20 B. Riley
LiqTech price target raised to $11 from $8 at B. Riley Securities
MDWD MediWound
$4.08 /

+0.26 (+6.81%)

06/29/21 Oppenheimer
MediWound NexoBrid CRL as expected, says Oppenheimer
03/02/21 Aegis
MediWound initiated with a Buy at Aegis
02/26/21 H.C. Wainwright
MediWound price target raised to $7 from $5.50 at H.C. Wainwright
10/19/20 BTIG
Vericel price target raised to $30 from $23 at BTIG
PSJ PwerShares Dynamic Software
$157.72 /

-2.98 (-1.85%)

RTPY Reinvent Technology Partners Y
$9.91 /

-0.02 (-0.20%)

SGTX Sigilon Therapeutics
$5.31 /

+0.32 (+6.41%)

07/19/21 Canaccord
Sigilon Therapeutics price target lowered to $43 from $62 at Canaccord
12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SIC Select Interior Concepts
$10.47 /

+0.18 (+1.75%)

03/16/21 B. Riley
Select Interior Concepts price target raised to $14 from $13 at B. Riley
02/02/21 B. Riley
Select Interior looks attractive relative to Blackstone deal, says B. Riley
01/22/21 B. Riley
Select Interior Concepts price target raised to $13 from $12 at B. Riley
09/11/20 Truist
Select Interior Concepts initiated with a Buy at Truist
USDP USD Partners
$6.66 /

-0.16 (-2.35%)

VIRI Virios Therapeutics
$5.64 /

-0.06 (-1.05%)

VYGG Vy Global Growth
$9.79 /

-0.04 (-0.41%)

SIC Select Interior Concepts
$10.47 /

+0.18 (+1.75%)

SGTX Sigilon Therapeutics
$5.31 /

+0.32 (+6.41%)

MDWD MediWound
$4.08 /

+0.26 (+6.81%)

LIQT LiqTech
$6.40 /

+0.19 (+3.06%)

INTT inTEST
$13.53 /

-0.65 (-4.58%)

IMXI International Money Express
$15.76 /

-0.09 (-0.57%)

ICL ICL
$7.06 /

-0.07 (-0.98%)

HMLP Hoegh LNG Partners
$17.76 /

-0.11 (-0.62%)

ESXB Community Bankers Trust
$10.65 /

-0.06 (-0.56%)

EARN Ellington Residential
$11.12 /

-0.06 (-0.54%)

CRTD Creatd
$3.17 /

-0.01 (-0.31%)

CHMI Cherry Hill Mortgage
$9.42 /

+0.04 (+0.43%)

CDAK Codiak
$16.35 /

-0.11 (-0.67%)

BTTR Better Choice Company
$3.47 /

-0.45 (-11.48%)

BBCP Concrete Pumping
$8.61 /

+0.13 (+1.53%)

ALGS Aligos Therapeutics
$15.07 /

-0.43 (-2.77%)

  • 29
    Jun
  • 01
    Jul
  • 17
    Jun
  • 15
    Jun
  • 25
    May
  • 25
    Mar
  • 12
    Feb
  • 17
    Dec
  • 03
    Dec
  • 04
    Dec
  • 16
    Oct
  • 14
    Oct
  • 01
    Oct
  • 14
    Aug
RTPY Reinvent Technology Partners Y
$9.91 /

-0.02 (-0.20%)

SGTX Sigilon Therapeutics
$5.31 /

+0.32 (+6.41%)

RTPY Reinvent Technology Partners Y
$9.91 /

-0.02 (-0.20%)

MDWD MediWound
$4.08 /

+0.26 (+6.81%)

INTT inTEST
$13.53 /

-0.65 (-4.58%)

ESXB Community Bankers Trust
$10.65 /

-0.06 (-0.56%)

DRTT Dirtt Environmental
$4.18 /

+0.03 (+0.72%)

CRTD Creatd
$3.17 /

-0.01 (-0.31%)

CRCT Cricut
$34.01 /

-3.02 (-8.16%)

CDAK Codiak
$16.35 /

-0.11 (-0.67%)

BBCP Concrete Pumping
$8.61 /

+0.13 (+1.53%)

ACHV Achieve Life Sciences
$7.29 /

-0.35 (-4.58%)

Over a week ago
Conference/Events
Codiak management to meet virtually with Evercore ISI » 04:55
07/19/21
07/19
04:55
07/19/21
04:55
CDAK

Codiak

$15.98 /

+0.73 (+4.79%)

Virtual Meeting to be…

Virtual Meeting to be held on July 19 hosted by Evercore ISI.

ShowHide Related Items >><<
CDAK Codiak
$15.98 /

+0.73 (+4.79%)

CDAK Codiak
$15.98 /

+0.73 (+4.79%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CDAK Codiak
$15.98 /

+0.73 (+4.79%)

  • 12
    Feb
  • 14
    Oct
CDAK Codiak
$15.98 /

+0.73 (+4.79%)

Conference/Events
Codiak management to meet virtually with Evercore ISI » 15:55
07/15/21
07/15
15:55
07/15/21
15:55
CDAK

Codiak

$15.35 /

-1.25 (-7.53%)

Virtual Meeting to be…

Virtual Meeting to be held on July 19 hosted by Evercore ISI.

ShowHide Related Items >><<
CDAK Codiak
$15.35 /

-1.25 (-7.53%)

CDAK Codiak
$15.35 /

-1.25 (-7.53%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CDAK Codiak
$15.35 /

-1.25 (-7.53%)

  • 12
    Feb
  • 14
    Oct
CDAK Codiak
$15.35 /

-1.25 (-7.53%)

Hot Stocks
VBI Vaccines announces Codiak BioSciences' CFO Linda Bain to join board » 08:23
07/07/21
07/07
08:23
07/07/21
08:23
VBIV

VBI Vaccines

$3.27 /

-0.035 (-1.06%)

, CDAK

Codiak

$18.34 /

+0.24 (+1.33%)

VBI Vaccines (VBIV)…

VBI Vaccines (VBIV) announced that Linda Bain, Chief Financial Officer of Codiak BioSciences has joined its Board of Directors. Ms. Bain is an accomplished financial and business executive with more than two decades of finance, strategy, and board experience in both small and large public companies in the biotechnology and pharmaceutical industry. As CFO of Codiak BioSciences (CDAK), Bain led the company through its initial public offering and first follow-on financing, building on the success of earlier-stage financing rounds. Ms. Bain plays a lead role in establishing Codiak's strategic direction and she built and leads finance and business operations, including investor relations and corporate communications, finance, accounting, facilities and information technology.

ShowHide Related Items >><<
VBIV VBI Vaccines
$3.27 /

-0.035 (-1.06%)

CDAK Codiak
$18.34 /

+0.24 (+1.33%)

VBIV VBI Vaccines
$3.27 /

-0.035 (-1.06%)

02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
08/27/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
08/27/20 Oppenheimer
VBI Vaccines' COVID vaccine has potential to be best-in-class, says Oppenheimer
08/26/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
CDAK Codiak
$18.34 /

+0.24 (+1.33%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
VBIV VBI Vaccines
$3.27 /

-0.035 (-1.06%)

CDAK Codiak
$18.34 /

+0.24 (+1.33%)

  • 12
    Feb
  • 14
    Oct
VBIV VBI Vaccines
$3.27 /

-0.035 (-1.06%)

CDAK Codiak
$18.34 /

+0.24 (+1.33%)

Over a month ago
Hot Stocks
Codiak BioSciences expands executive leadership » 08:16
06/15/21
06/15
08:16
06/15/21
08:16
CDAK

Codiak

$25.48 /

-1.18 (-4.43%)

Codiak BioSciences…

Codiak BioSciences announced the promotion of Sriram Sathyanarayanan, Ph.D., who has led Codiak's preclinical research efforts for the past four years to Chief Scientific Officer. Additionally, Konstantin Konstantinov, Ph.D., who has led the company's manufacturing and process sciences since Codiak's inception, has been named Chief Technology Officer. Prior to this appointment, Sathyanarayanan was Senior Vice President, Preclinical Development. Konstantinov most recently held the position of Executive Vice President, Manufacturing and Process Sciences.

ShowHide Related Items >><<
CDAK Codiak
$25.48 /

-1.18 (-4.43%)

CDAK Codiak
$25.48 /

-1.18 (-4.43%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CDAK Codiak
$25.48 /

-1.18 (-4.43%)

  • 12
    Feb
  • 14
    Oct
CDAK Codiak
$25.48 /

-1.18 (-4.43%)

Hot Stocks
Codiak presents new preclinical data from its engEx Platform » 08:35
05/11/21
05/11
08:35
05/11/21
08:35
CDAK

Codiak

$16.40 /

-2.01 (-10.92%)

Codiak BioSciences…

Codiak BioSciences announced new preclinical data from programs from its engEx Platform showing the potential therapeutic applications of engineered exosomes. The data, which include results from the IND-enabling studies for exoASO-STAT6, immune evasion data from Codiak's exoAAV gene therapy platform, data showing the versatility of Codiak's exoVACC vaccine platform, and Codiak's ability to engineer specific cell uptake were presented at the virtual 24th Annual Meeting of the American Society of Gene and Cell Therapy. Codiak's proprietary engEx Platform enables the company to engineer exosomes with distinct properties, load them with various therapeutic molecules and alter tropism so they reach specific cellular targets. Codiak has two programs in clinical development and expects to file an IND for exoASO-STAT6 by the end of the year. exoASO-STAT6 Demonstrates Immune-Mediated Anti-Tumor Activity. Data presented at ASGCT from Codiak's exoASO-STAT6 program confirm results presented earlier this year showing potent local and systemic anti-tumor activity. Exosome-mediated delivery of an ASO results in enhanced uptake and improved silencing of STAT6 in tumor associated macrophages compared to ASO administration without an exosome. This activity, which was evident both in vitro and in vivo and across species, was persistent for up to 10 days and resulted in effective reprogramming of immunosuppressive macrophages to a pro-inflammatory phenotype. Efficacy studies of exoASO-STAT6 in multiple tumor models revealed dose-dependent single-agent activity, including 94% tumor growth inhibition and 60% complete responses at the efficacious dose in a CT26 tumor model and 62% reduction in tumor mass and complete elimination of tumor lesions in an orthotopic model of HCC unresponsive to other immunotherapies. exoVACC Induces Robust, Tunable and Broad Immune Response. The data presented at ASGCT show that this platform enables antigen-specific immune responses that can be modulated through antigen orientation and adjuvant loading. Further, multiple exoVACC vaccine constructs induced superior systemic and tissue-resident immune responses via various routes of administration compared to conventional vaccine formulations in animal models. Immune-Silent Nature of Exosomes Provides Potential Strategy to Enhance AAV Delivery. Codiak presented new data at ASGCT that show that exosomes also have potential utility in overcoming the limitations of current adeno-associated virus vectors used for the delivery of gene therapies. Engineered Exosomes with Altered Cellular Tropism Instigate Preferential Uptake in Neuronal Cells. Results from multiple in vitro and in vivo studies have demonstrated the ability of the engEx Platform to modulate exosome tropism and drive uptake into specific cell types.

ShowHide Related Items >><<
CDAK Codiak
$16.40 /

-2.01 (-10.92%)

CDAK Codiak
$16.40 /

-2.01 (-10.92%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CDAK Codiak
$16.40 /

-2.01 (-10.92%)

  • 12
    Feb
  • 14
    Oct
CDAK Codiak
$16.40 /

-2.01 (-10.92%)

Hot Stocks
Codiak appoints Jennifer Wheler as Chief Medical Officer » 08:05
05/10/21
05/10
08:05
05/10/21
08:05
CDAK

Codiak

$18.45 /

+0.27 (+1.49%)

Codiak BioSciences…

Codiak BioSciences announced the appointment of Jennifer Wheler, M.D. as Chief Medical Officer. Dr. Wheler, who joins the company's Executive Leadership Team and reports to president and CEO Douglas Williams, Ph.D., will provide leadership and direction for Codiak's pipeline of clinical development programs through early-stage trials to global regulatory submissions. Benny Sorensen, M.D., Ph.D., who has led the preclinical to clinical translational work and clinical strategy for Codiak for the past five years will become Senior Vice President, Strategic Projects. Dr. Sorensen will report to president and CEO Douglas Williams and continue as a member of Codiak's Executive Leadership Team. Dr. Wheeler served most recently as chief medical officer of Bicara Therapeutics, where she designed and led the first-in-human Phase I/II trial for the company's bi-functional antibody candidate.

ShowHide Related Items >><<
CDAK Codiak
$18.45 /

+0.27 (+1.49%)

CDAK Codiak
$18.45 /

+0.27 (+1.49%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CDAK Codiak
$18.45 /

+0.27 (+1.49%)

  • 12
    Feb
  • 14
    Oct
CDAK Codiak
$18.45 /

+0.27 (+1.49%)

Over a quarter ago
Hot Stocks
Codiak BioSciences Inc trading resumes  13:52
04/22/21
04/22
13:52
04/22/21
13:52
CDAK

Codiak

$12.98 /

+1.33 (+11.42%)

 
ShowHide Related Items >><<
CDAK Codiak
$12.98 /

+1.33 (+11.42%)

CDAK Codiak
$12.98 /

+1.33 (+11.42%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CDAK Codiak
$12.98 /

+1.33 (+11.42%)

  • 12
    Feb
  • 14
    Oct
CDAK Codiak
$12.98 /

+1.33 (+11.42%)

Hot Stocks
Codiak BioSciences Inc trading halted, volatility trading pause  13:47
04/22/21
04/22
13:47
04/22/21
13:47
CDAK

Codiak

$12.74 /

+1.09 (+9.36%)

 
ShowHide Related Items >><<
CDAK Codiak
$12.74 /

+1.09 (+9.36%)

CDAK Codiak
$12.74 /

+1.09 (+9.36%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CDAK Codiak
$12.74 /

+1.09 (+9.36%)

  • 12
    Feb
  • 14
    Oct
CDAK Codiak
$12.74 /

+1.09 (+9.36%)

Hot Stocks
Codiak announces publication of data on exoSTING preclinical development » 07:09
04/22/21
04/22
07:09
04/22/21
07:09
CDAK

Codiak

$11.65 /

-0.29 (-2.43%)

Codiak BioSciences…

Codiak BioSciences announced the online publication of a new manuscript, exoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance, in Communications Biology, a Nature Research publication. exoSTING is a novel engineered exosome therapeutic candidate currently being investigated in a Phase 1/2 clinical trial as a single agent for the treatment of multiple solid tumors. This publication details the findings from the preclinical development program and highlights the potential of exoSTING to stimulate a broad immune response without the detrimental effects on intratumoral T cells observed with other STING agonists. exoSTING is one of two Codiak programs currently in clinical development. Engineered using the company's proprietary engEx(TM) Platform to provide targeted delivery of Codiak's STING agonist to antigen presenting cells (APCs) in the tumor microenvironment, exoSTING demonstrates greater than 100-fold increased potency in in vivo tumor models and increased tumor retention and lower levels of systemic inflammatory cytokine production as compared to free STING agonist. Additionally, exoSTING demonstrates CD8 T-cell preservation, expansion, Th1 polarization and establishment of systemic antigen-specific T-cell mediated immune responses across a wide dose range without evidence of immune ablation as seen with free STING agonists. A Phase 1/2 dose escalation clinical trial of exoSTING is currently underway investigating safety, tolerability, pharmacological activity, and objective tumor response in patients with advanced/metastatic, recurrent, injectable solid tumors, with a focus on tumors likely to be enriched in APCs. Examples of such tumors include metastatic head and neck squamous cell cancer, triple negative breast cancer, anaplastic thyroid carcinoma, and cutaneous squamous cell carcinoma. Safety, biomarker and preliminary efficacy data from the dose-escalation phase of the trial are expected in mid-2021.

ShowHide Related Items >><<
CDAK Codiak
$11.65 /

-0.29 (-2.43%)

CDAK Codiak
$11.65 /

-0.29 (-2.43%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CDAK Codiak
$11.65 /

-0.29 (-2.43%)

  • 12
    Feb
  • 14
    Oct
CDAK Codiak
$11.65 /

-0.29 (-2.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.